Coherence, a company developing a button-sized brain implant for cancer detection and electrical intervention, secured a $45 million seed round as it pushes toward its first chronic human trial in glioblastoma. The financing brings together OpenAI’s Startup Fund and Peter Thiel’s Founders Fund, alongside participation from Lux Capital and other named backers. Coherence’s SOMA implant aims to monitor tumor electrical signals in real time and deliver stimulation, while pairing with an over-ear wearable and an app for data and therapy history. Early safety testing in consenting patients has already involved placing implants for 30 minutes during other surgeries, with plans for continued escalation. The deal underscores growing investor appetite for device-led oncology approaches that combine sensing and intervention, and it may accelerate competitive dynamics around next-generation closed-loop neuro-oncology platforms.